(via TheNewswire)
Tampa, Florida, United States – TheNewswire – November 20, 2025 - CTT Pharmaceutical Holdings, Inc.(OTCQB:CTTH) is pleased to announce that the CEO of CTT Pharma will issue a letter to shareholders on December 2, 2025. The letter willoutline several initiatives underway that will advance CTT’s strategic direction, includingupdates on our S-1 filing, which will allow CTT to become a full SEC reporting company. Thus allowing CTT access to funding from our equity line of credit, and help accelerate growth by monetizing the company’s patents. The letter will also includeinformation about ongoing operational initiatives including steps toward preparing for manufacturing capabilities, as well as updates on strategic partners who are aligned with CTT’s commercialization strategy.
Finally, shareholders will receive an update on the recent submission of our peer-reviewed scientific manuscript whichbrings to light the scientific foundation behind what we believe is a transformative technology in therapeutic drug delivery.
CTT Pharma – 813-606-0060
Copyright (c) 2025 TheNewswire - All rights reserved.
© Copyright (c) 2025 TheNewswire - All rights reserved.